Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.
April 16, 2024 08:30 ET
|
TELOMIR PHARMACEUTICALS, INC.
Telomir-1 elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase that protects the DNA and genetic material in chromosomes to combat aging ...
Telomir Pharmaceuticals’ Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024
April 02, 2024 08:30 ET
|
TELOMIR PHARMACEUTICALS, INC.
Telomir’s pre-clinical studies demonstrate its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase ...
UPDATE – Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines
March 29, 2024 16:44 ET
|
TELOMIR PHARMACEUTICALS, INC.
Study to determine the efficacy of Telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases This study is believed to be the first and only known study focused on...
Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines
March 26, 2024 08:30 ET
|
TELOMIR PHARMACEUTICALS, INC.
Study to determine the efficacy of Telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases This study is believed to be the first and only known study focused on...
Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th
March 22, 2024 08:30 ET
|
TELOMIR PHARMACEUTICALS, INC.
Poster presentation delivers pre-clinical results that demonstrate that its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells The New York Times...
Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate’s Potential in DNA Age Reversal Science
March 14, 2024 08:30 ET
|
TELOMIR PHARMACEUTICALS, INC.
BALTIMORE, March 14, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and...
Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference
March 07, 2024 08:30 ET
|
TELOMIR PHARMACEUTICALS, INC.
BALTIMORE, March 07, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and...
Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal
March 05, 2024 08:30 ET
|
TELOMIR PHARMACEUTICALS, INC.
Dr. Roizen to provide expertise on longevity and aging Research on aging involving Telomir’s lead product candidate focused on reversing age-related decline and the extension of human life ...
Telomir Pharmaceuticals Announces Closing of Initial Public Offering
February 13, 2024 16:05 ET
|
TELOMIR PHARMACEUTICALS, INC.
BALTIMORE, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and...
Telomir Pharmaceuticals Announces Pricing of Initial Public Offering
February 08, 2024 17:30 ET
|
TELOMIR PHARMACEUTICALS, INC.
BALTIMORE, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, is developing...